EXtended Therapy in Genotype 3 Infected Patients Who do Not AChieve a Treatment Response at Week 4 (RVR) But do Achieve a Complete Early Virologic Response (cEVR).
Phase of Trial: Phase III
Latest Information Update: 28 Sep 2011
At a glance
- Drugs Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms EXACT-R(3)
- 28 Sep 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 28 Sep 2011 Planned end date changed from 1 Aug 2015 to 1 Jun 2011 as reported by ClinicalTrials.gov.
- 03 Apr 2010 New trial record